Gadobenic acid

Generic Name: Gadobenic acid

Brand Names: Multihance

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈GdN_₃O_₁₁

CAS Number: 113662-23-0

Unique Ingredient Identifier: 15G12L5X8K

Background: Gadobenic acid (in the form of gadobenate dimeglumine) is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding lea...

Indication: Gadobenate dimeglumine is indicated for use in magnetic resonance imaging (MRI) of the central nervous system in adult and pediatric patients in order to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. It is also indicated for use in magnetic resonance angiography (MRA) to evaluate adul...

Associated Conditions: Vascular Occlusion

Associated Therapies: -

Clinical Trials

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

Phase 3

Not yet recruiting

Conditions: Congenital Heart Disease

Interventions: Drug: Gadobenate dimeglumine
Drug: Gadopiclenol

First Posted Date: 2024-05-09

Last Posted Date: 2024-05-09

Lead Sponsor: University of California, San Diego

Target Recruit Count: 160

Registration Number: NCT06406517

Locations: 🇺🇸
University of California San Diego Health, San Diego, California, United States

Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

Phase 4

Recruiting

Conditions: Oligometastatic Disease
Liver Metastases
Colorectal Cancer

Interventions: Drug: Gadoxetate disodium
Drug: Gadobenate dimeglumine

First Posted Date: 2021-07-22

Last Posted Date: 2024-12-06

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 55

Registration Number: NCT04973007

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Phase 2

Not yet recruiting

Conditions: Prostate Carcinoma

Interventions: Drug: Fluorine F 18 DCFPyL
Drug: Gadobenate Dimeglumine
Drug: Gadobutrol
Procedure: Magnetic Resonance Imaging
Procedure: Multiparametric Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Transrectal Ultrasonography Guided Biopsy

First Posted Date: 2021-06-02

Last Posted Date: 2022-08-03

Lead Sponsor: Northwestern University

Target Recruit Count: 106

Registration Number: NCT04910425

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Phase 4

Recruiting

Conditions: Motor Function
Cognitive Function
Contrast Media

Interventions: Procedure: Motor Tests
Procedure: Cognitive Tests
Procedure: Unenhanced-MRI of the brain
Procedure: Gadolinium Measurements
Drug: Gadoxetate disodium
Drug: Gadoterate meglumine
Drug: Gadobenate dimeglumine
Drug: Gadobutrol
Drug: Gadodiamide
Drug: Gadoteridol

First Posted Date: 2020-05-04

Last Posted Date: 2024-05-17

Lead Sponsor: Guerbet

Target Recruit Count: 2076

Registration Number: NCT04373564

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇧🇷
Hospital Santa Marta, Taguatinga, Distrito Federal, Brazil

and more 43 locations

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Not Applicable

Completed

Conditions: Brain Neoplasm
Recurrent Malignant Brain Neoplasm
Lymphoma
Metastatic Malignant Neoplasm in the Brain

Interventions: Drug: Gadobenate Dimeglumine
Drug: Gadobutrol
Procedure: Magnetic Resonance Imaging

First Posted Date: 2019-10-21

Last Posted Date: 2022-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT04132843

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Phase 2

Completed

Conditions: Breast Cancer
Ductal Carcinoma in Situ - Category

Interventions: Drug: (18F)FES
Drug: Gadobenate dimeglumine

First Posted Date: 2018-10-12

Last Posted Date: 2024-01-19

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 13

Registration Number: NCT03703492

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients

Completed

Conditions: Central Nervous System Diseases
Central Nervous System Neoplasms

Interventions: Drug: MultiHance

First Posted Date: 2017-05-10

Last Posted Date: 2018-07-18

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 352

Registration Number: NCT03147989

Locations: 🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States

QSM and Regional DCE MRI Permeability Using GOCART Technique

Withdrawn

Conditions: Intracranial Neoplasm

Interventions: Device: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Drug: Gadobenate Dimeglumine
Drug: Gadoterate Meglumine
Device: Magnetic Resonance Imaging

First Posted Date: 2017-03-27

Last Posted Date: 2021-04-05

Lead Sponsor: University of Southern California

Registration Number: NCT03091803

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Not Applicable

Terminated

Conditions: Adult Anaplastic (Malignant) Meningioma
Adult Anaplastic Oligodendroglioma
Adult Brain Stem Glioma
Adult Choroid Plexus Neoplasm
Adult Diffuse Astrocytoma
Adult Ependymoblastoma
Adult Ependymoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Drug: Gadobenate Dimeglumine
Drug: Gadobutrol
Radiation: Gadopentetate Dimeglumine

First Posted Date: 2016-11-18

Last Posted Date: 2017-03-27

Lead Sponsor: University of Southern California

Target Recruit Count: 14

Registration Number: NCT02967380

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Phase 2

Completed

Conditions: CNS Lesion
Blood Brain Barrier Defect

Interventions: Drug: P03277
Drug: Gadobenate dimeglumine
Device: MRI

First Posted Date: 2015-12-17

Last Posted Date: 2021-10-25

Lead Sponsor: Guerbet

Target Recruit Count: 312

Registration Number: NCT02633501

Locations: 🇮🇹
Ospedali Riuniti di Ancona, Ancona, Italy
🇮🇹
AO S. Andrea Universita La Sapienza, Roma, Italy
🇭🇺
Pecsi Tudomany Egyetem Klinikai kozpont Idegsebeszeti Klinica, Pécs, Hungary

and more 25 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy